Latest News
Sanaregen receives FDA clearance for retinal degeneration clinical trial
3 March 2026 - Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, on Tuesday announced US Food and Drug Administration (FDA) clearance to begin a Phase I/II clinical trial of SVT-001, its investigational cell therapy.The t...
Esperion to acquire Corstasis, expanding cardiovascular portfolio
3 March 2026 - US commercial stage biopharmaceutical company Esperion Therapeutics Inc (NASDAQ:ESPR) on Tuesday announced a definitive agreement to acquire privately held Corstasis Therapeutics Inc, adding Enbumyst (bumetanide nasal spray) to its car...
Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial
3 March 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company, on Monday reported positive topline results from its Phase III clinical trial evaluating zemprocitinib in patients with moderate-to-severe atopic dermat...
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
3 March 2026 - Clinical-stage biotechnology company ReviR Therapeutics announced on Monday that the first participant has been dosed in the First-in-Human (FIH) Phase 1 clinical trial of its lead candidate, RTX-117.This clinical progress follows the ...
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
3 March 2026 - Breckenridge Pharmaceutical Inc, the US subsidiary of Spain-based Towa International, announced on Monday the launch of Pomalidomide Capsules, a generic version of Pomalyst by Celgene (now Bristol Myers Squibb), within the oncology the...